Likewise, venous thromboembolic events represent both initial manifestations of an underlying MPN but may also be associated with a JAK2 V617F mutation without the clinical phenotype of a concomitant myeloid neoplasm. This evidence concerns the gene JAK2 and myeloproliferative disorder.